Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
Jinyi Tang, Cong Zeng, Thomas M Cox, et al.
Science Immunology (2022) Vol. 7, Iss. 76
Open Access | Times Cited: 271

Showing 51-75 of 271 citing articles:

Comparative single-cell analysis reveals IFN-γ as a driver of respiratory sequelae after acute COVID-19
Chaofan Li, Wei Qian, Xiaoqin Wei, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 756
Closed Access | Times Cited: 15
SARS-CoV-2 correlates of protection from infection against variants of concern
Kaiyuan Sun, Jinal N. Bhiman, Stefano Tempia, et al.
Nature Medicine (2024) Vol. 30, Iss. 10, pp. 2805-2812
Closed Access | Times Cited: 11
Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity
Sabryna Nantel, Salma Sheikh‐Mohamed, Gary Chao, et al.
Mucosal Immunology (2024) Vol. 17, Iss. 2, pp. 201-210
Open Access | Times Cited: 9
A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
Jun Liu, Li Wang, Alexandra Kurtesi, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Metal-based nanomedicines and their immunoregulatory effects
Hang Liu, Mingjing Cao, Chunying Chen
Chinese Science Bulletin (Chinese Version) (2025)
Closed Access | Times Cited: 1
Reconsideration of Antinucleocapsid IgG Antibody as a Marker of SARS-CoV-2 Infection Postvaccination for Mild COVID-19 Patients
Santosh Dhakal, Tong Yu, Anna Yin, et al.
Open Forum Infectious Diseases (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 38
Bioinspired Lipid Nanocarriers for RNA Delivery
Alex Golubovic, Shannon J. Tsai, Bowen Li
ACS Bio & Med Chem Au (2023) Vol. 3, Iss. 2, pp. 114-136
Open Access | Times Cited: 21
Promises and challenges of mucosal COVID-19 vaccines
Abhay P. S. Rathore, Ashley L. St. John
Vaccine (2023) Vol. 41, Iss. 27, pp. 4042-4049
Open Access | Times Cited: 18
Mucosal vaccination: onward and upward
Catherine Jia‐Yun Tsai, Jacelyn M. S. Loh, Kohtaro Fujihashi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 885-899
Open Access | Times Cited: 18
Prevention of respiratory virus transmission by resident memory CD8+ T cells
Ida Uddbäck, Sarah Michalets, Ananya Saha, et al.
Nature (2023) Vol. 626, Iss. 7998, pp. 392-400
Open Access | Times Cited: 18
A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases
Fabian Bohländer
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses
Divya Sinha, Melyssa Yaugel-Novoa, Louis Waeckel, et al.
Antiviral Research (2024) Vol. 223, pp. 105823-105823
Closed Access | Times Cited: 8
Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges
Bryce M. Warner, Jacob G. E. Yates, Robert Vendramelli, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines
Jimin Lee, Cameron Stewart, Alexandra Schäfer, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Yu Gao, Liang Yang, Zhenning Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity
Ninaad Lasrado, Marjorie Rowe, Katherine McMahan, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 770
Open Access | Times Cited: 8
Tissue-resident memory T cells in protective immunity to influenza virus
Seung‐Woo Lee, Karen Yeung, Tania H. Watts
Current Opinion in Virology (2024) Vol. 65, pp. 101397-101397
Open Access | Times Cited: 7
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
Stefan Slamanig, Irene González‐Domínguez, Lauren A Chang, et al.
EBioMedicine (2024) Vol. 105, pp. 105185-105185
Open Access | Times Cited: 7
Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective
Yuexiu Zhang, Michelle Chamblee, Jiayu Xu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines
Chunhong Dong, Wandi S. Zhu, Lai Wei, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets
Ian R. Woodward, Catherine A. Fromen
Annual Review of Biomedical Engineering (2024) Vol. 26, Iss. 1, pp. 307-330
Closed Access | Times Cited: 6
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Ziyi Bai, Dandan Wan, Tianxia Lan, et al.
ACS Nano (2024) Vol. 18, Iss. 36, pp. 24650-24681
Open Access | Times Cited: 6
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, et al.
Nature Immunology (2024) Vol. 25, Iss. 10, pp. 1913-1927
Open Access | Times Cited: 6
A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern
Jingyi Yang, Meiqin Liu, Lin Liu, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 11, pp. 1279-1289
Open Access | Times Cited: 28
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
Raju Sunagar, Sai Prasad, Raches Ella, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 27

Scroll to top